Payment overview · 2025
General Payments
$2,360.86
153 reported records · 20 companies
Healthcare provider profile · identity verified
Scott David Anderson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1366403479
Verified facts
What the public records show
CMS Open Payments records show Scott David Anderson, D.O. received $2,360.86 in general payments during 2025 across 153 reported records.
ABBVIE INC. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $398.50 | 16.9% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $308.21 | 13.1% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $290.79 | 12.3% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.47 | 8.1% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.55 | 6.8% | 13 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $144.01 | 6.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.37 | 6.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.32 | 5.3% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $109.44 | 4.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $99.56 | 4.2% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $77.63 | 3.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $61.90 | 2.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $61.78 | 2.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.27 | 2.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.84 | 1.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.33 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.62 | 1.0% | 1 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $20.00 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.46 | 0.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $13.81 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,360.86 | 153 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $349.70 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $256.23 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $239.00 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $155.21 | 12 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $144.01 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $140.37 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.19 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.85 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.32 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.32 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.17 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $109.44 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.46 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.46 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.68 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $85.01 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $83.79 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $82.50 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $77.63 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $69.21 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $69.21 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $69.21 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $65.85 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $61.78 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.27 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $41.01 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.36 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.39 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $9.39 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $8.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 132 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 171 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 239 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 138 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
138 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
171 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
171 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
239 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
59 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 956 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 643 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 141 |
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 140 |
| Gabapentin | Gabapentin | 468 | 110 |
| Alprazolam | Alprazolam | 446 | 91 |
| Lisinopril | Lisinopril | 443 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 357 | 79 |
| Trazodone Hcl | Trazodone Hcl | 336 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 335 | 90 |
| Losartan Potassium | Losartan Potassium | 332 | 89 |
| Omeprazole | Omeprazole | 322 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 321 | 70 |
| Tramadol Hcl | Tramadol Hcl | 302 | 66 |
| Meloxicam | Meloxicam | 295 | 75 |
| Potassium Chloride | Potassium Chloride | 294 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 85 |
| Furosemide | Furosemide | 262 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 53 |
| Lorazepam | Lorazepam | 247 | 55 |
| Famotidine | Famotidine | 240 | 59 |
| Allopurinol | Allopurinol | 239 | 63 |
| Ozempic | Semaglutide | 239 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 218 | 55 |
| Metformin Hcl | Metformin Hcl | 214 | 56 |
| Eliquis | Apixaban | 213 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 61 |
| Montelukast Sodium | Montelukast Sodium | 198 | 50 |
| Clonazepam | Clonazepam | 195 | 30 |
| Carvedilol | Carvedilol | 172 | 46 |
| Ezetimibe | Ezetimibe | 172 | 57 |
| Jardiance | Empagliflozin | 171 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 35 |
| Azithromycin | Azithromycin | 162 | 127 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 158 | 34 |
| Prednisone | Prednisone | 147 | 92 |
| Simvastatin | Simvastatin | 145 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 56 |
| Synthroid | Levothyroxine Sodium | 138 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 44 |
| Farxiga | Dapagliflozin Propanediol | 132 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 25 |
| Glimepiride | Glimepiride | 120 | 28 |
| Celecoxib | Celecoxib | 109 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 25 |
| Mounjaro | Tirzepatide | 105 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 25 |
| Sertraline Hcl | Sertraline Hcl | 104 | 32 |
| Temazepam | Temazepam | 104 | 22 |
| Methylprednisolone | Methylprednisolone | 102 | 90 |
| Ondansetron Odt | Ondansetron | 102 | 49 |
| Spironolactone | Spironolactone | 100 | 28 |
| Finasteride | Finasteride | 98 | 31 |
| Donepezil Hcl | Donepezil Hcl | 95 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 25 |
| Memantine Hcl | Memantine Hcl | 92 | 23 |
| Bupropion Xl | Bupropion Hcl | 91 | 24 |
| Estradiol | Estradiol | 91 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 54 |
| Testosterone Cypionate | Testosterone Cypionate | 89 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 62 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 20 |
| Pregabalin | Pregabalin | 84 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 50 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 82 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 23 |
| Irbesartan | Irbesartan | 81 | 19 |
| Propranolol Hcl | Propranolol Hcl | 81 | 13 |
| Repatha Sureclick | Evolocumab | 80 | 20 |
| Diazepam | Diazepam | 77 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 28 |
| Fluconazole | Fluconazole | 74 | 38 |
| Valsartan | Valsartan | 74 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 58 |
| Metformin Hcl Er | Metformin Hcl | 69 | 21 |
| Buspirone Hcl | Buspirone Hcl | 68 | 22 |
| Ketoconazole | Ketoconazole | 66 | 29 |
| Praluent Pen | Alirocumab | 66 | 12 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 11 |
| Amoxicillin | Amoxicillin | 63 | 45 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 12 |
| Mupirocin | Mupirocin | 63 | 41 |
| Valacyclovir | Valacyclovir Hcl | 63 | 29 |
| Baclofen | Baclofen | 62 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 15 |
| Bumetanide | Bumetanide | 59 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 59 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Aripiprazole | Aripiprazole | 57 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 22 |
| Benazepril Hcl | Benazepril Hcl | 54 | suppressed |
| Cefdinir | Cefdinir | 53 | 49 |
| Colestipol Hcl | Colestipol Hcl | 51 | 13 |
| Meclizine Hcl | Meclizine Hcl | 51 | 19 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Atenolol | Atenolol | 50 | 18 |
| Chlorthalidone | Chlorthalidone | 49 | 12 |
| Clonidine Hcl | Clonidine Hcl | 49 | 13 |
| Sucralfate | Sucralfate | 49 | 16 |
| Topiramate | Topiramate | 49 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 12 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 14 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Nystatin | Nystatin | 45 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 13 |
| Carisoprodol | Carisoprodol | 44 | suppressed |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 18 |
| Promethazine Hcl | Promethazine Hcl | 44 | 12 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 40 | 12 |
| Nitroglycerin | Nitroglycerin | 39 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 21 |
| Levofloxacin | Levofloxacin | 37 | 35 |
| Methocarbamol | Methocarbamol | 37 | 16 |
| Premarin | Estrogens, Conjugated | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Linzess | Linaclotide | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Armour Thyroid | Thyroid,pork | 35 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 13 |
| Glipizide | Glipizide | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 23 |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 12 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 13 |
| Nexletol | Bempedoic Acid | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 20 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 17 |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Triazolam | Triazolam | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levoxyl | Levothyroxine Sodium | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Clonidine | Clonidine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,360.86 · 153 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VYEPTI, Wegovy, XIFAXAN, XYOSTED, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error